Fujii, Hironori; Matsuhashi, Nobuhisa; Kitahora, Mika; Takahashi, Takao; Hirose, Chiemi; Iihara, Hirotoshi; Yamada, Yunami; Watanabe, Daichi; Ishihara, Takuma; Suzuki, Akio; Yoshida, Kazuhiro published an article in 2020, the title of the article was Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione And the article contains the following content:
TAS-102 is effective for treating patients with metastatic colorectal cancer (mCRC). This study determined whether combining bevacizumab (Bmab) with TAS-102 improves clin. outcomes in refractory mCRC. We retrospectively analyzed data from Japanese patients with refractory mCRC who received TAS-102 (35 mg/m2, twice a day) with (T-B group) or without Bmab (TAS-102 monotherapy; T group) between July 2014 and Dec. 2018. The primary endpoint was median overall survival (OS), and secondary endpoints were median time to treatment failure, overall response rate, and the incidence of adverse events. Clin. outcomes were compared using propensity score matched anal. Data from 57 patients were analyzed (T-B group: 21 patients, T group: 36 patients). Median OS was significantly longer in the T-B group than the T group (14.4 mo vs. 4.5 mo, p < .001). Cox proportional hazard anal. showed that combination therapy with Bmab was significantly correlated with OS. Propensity score matched anal. confirmed that the median OS was significantly longer in the T-B group than the T group (14.4 mo vs. 6.1 mo, p = .006) and that there was a significant correlation between Bmab and OS. The incidence of hypertension (grade ≥2) as an adverse event was significantly higher in the T-B group than the T group (23.8% vs. 0.0%, p = .005), whereas other adverse events were comparable between the two groups. Treatment with Bmab in combination with TAS-102 is significantly associated with improved clin. outcomes in patients with mCRC refractory to standard therapies. Combining bevacizumab (Bmab) with TAS-102 significantly improved overall survival and several prognostic indicators in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies, with manageable toxicities. Treatment with Bmab in combination with TAS-102 is significantly associated with improved clin. outcomes in patients with mCRC. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione
The Article related to bevacizumab tas102 anticancer agent metastatic colorectal cancer, bevacizumab, colorectal neoplasms, drug-related adverse reactions, survival, trifluridine, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia